# EDGAR Filing Document

**Accession Number:** 0002044725
**File Stem:** 0001193125-26-043771
**Filing Date:** 2026-2
**Character Count:** 39308
**Document Hash:** 31bf2b2726ef9145dd9c03168c076f54
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-043771.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001193125-26-043771

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 42

**CONFORMED PERIOD OF REPORT**: 20260210

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evommune, Inc.
- **CENTRAL INDEX KEY:** 0002044725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 850742575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42938
- **FILM NUMBER:** 26613541

**BUSINESS ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 223-7745

**MAIL ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** February 10, 2026

------

Evommune, Inc.

**(Exact Name of Registrant as Specified in Its Charter)** 

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-42938 | 85-0742575 |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |
| 1841 Page Mill Road**,** Suite 100<br>Palo Alto**,** CA |  | 94304 |
| (Address of Principal Executive Offices) |  | (Zip Code) |

---

**Registrant's Telephone Number, Including Area Code: (**925**)** 247-4487

**N/A** 

**(Former Name or Former Address, if Changed Since Last Report)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | EVMN | The New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

As reported under Item 8.01 of this Current Report on Form 8-K, on February 10, 2026, Evommune, Inc. (the "Company") issued a press release titled "Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis". A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

On February 10, 2026, the Company will host a webcast to discuss the results from the Company's EVO301 Phase 2a trial in adult patients with moderate-to-severe atopic dermatitis ("AD"). The live webcast presentation will also be available on the "News & Events" page of the Company's website at https://ir.evommune.com/news-events/ir-calendar. A copy of the presentation is being furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The Company's website and any information contained on the Company's website are not incorporated by reference into this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

The information in this Item 7.01, including Exhibits 99.1 and 99.2 hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 8.01 Other Events.**

On February 10, 2026, the Company announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 ("IL-18") binding protein and an anti-serum albumin Fab-associated domain, achieved highly statistically significant outcomes in adult patients with moderate-to-severe AD. The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/kg on day 1 and day 28 (n=48 active, n=22 placebo) over 12 weeks.

**Key data highlights include:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Primary Endpoint:** The trial met its primary endpoint; a Bayesian success criterion related to the difference between active and placebo in the percent improvement in baseline in the Eczema Area and Severity Index ("EASI"). While the success criterion required at least 75% of the posterior distribution to be an improvement of at least 8% over placebo, the results of the study demonstrated 99.8% of the posterior distribution met that threshold. Furthermore, when analyzed by the more commonly used frequentist method, statistical significance was achieved at weeks 4, 8 and 12 at p<0.01.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**% Reduction in EASI at weeks 4, 8 and 12:**

![img115706865_0.gif](img115706865_0.gif)

Additionally, 23% of patients treated with EVO301 (vs 0% placebo) achieved vIGA-AD 0/1 (percent of patients achieving a score of 0 or 1 on the validated Investigator's Global Assessment for Atopic Dermatitis with ≥ 2-point reduction from baseline) at week 12.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Pharmacokinetics ("PK"):** Consistent with the Phase 1 healthy volunteer trial; PK and target engagement data continue to support a Q4 week dosing regimen.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Safety Profile:** EVO301 was well tolerated, with no related serious or severe adverse events reported, no treatment related discontinuations due to adverse events and no meaningful differences in events between the active and placebo groups.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Biomarkers:** Robust reduction of both Th2 and non Th2 inflammatory biomarkers in atopic dermatitis including CCL-17 (TARC), CCL-22 and IL-22.

------

**Item 9.01 Financial Statements and Exhibits.**

<u>(d) Exhibits</u>.

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 99.1 | [<u>Press Release, dated February 10, 2026, titled "Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis"</u>](evmn-ex99_1.htm) |
| 99.2 | [<u>Evommune, Inc. Presentation, dated February 2026</u>](evmn-ex99_2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Evommune, Inc. | Evommune, Inc. |
| Date: February 10, 2026 | By: | /s/ Luis Peña |
|  |  | Luis Peña |
|  |  | President and Chief Executive Officer |

---

------

## Exhibit 99.1

![img108483603_0.jpg](img108483603_0.jpg)

**Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis**

*- Trial met primary efficacy endpoint at week 12* 

*- EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo*

*- 33% placebo-adjusted improvement in EASI at week 12*

*- 23% of EVO301 patients achieved IGA 0/1 at week 12*

*- Company to hold conference call and webcast at 8:30 a.m. ET today*

**Palo Alto, CA., and New York, NY., Feb. 10, 2026 –** Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated domain, achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis (AD). The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/kg on day 1 and day 28 (n=48 active, n=22 placebo) over 12 weeks.

"These data underscore that impacting pathways beyond only Th2 biology can meaningfully contribute to AD disease activity. EVO301's ability to target the novel IL-18 mechanism and show clinically relevant treatment activity without side effects, could offer real benefit for patients in such a heterogeneous disease," said Dr. Mark G. Lebwohl, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai. "There is an urgent need for new treatment options for the growing number of patients suffering from AD. With rapid onset and durable responses, as evidenced by meeting the primary endpoint at weeks 4, 8 and 12 after only two doses, this trial supports the potential of EVO301 to become a front-line biologic treatment in AD, if approved."

"This is a big milestone for Evommune and we are pleased to report unequivocally positive data that validate IL-18 inhibition and show significant activity of EVO301 in moderate-to-severe AD patients. These data support our plans to move EVO301 into a Phase 2b dose-ranging trial where we can optimize the dose and seek to further improve patient outcomes," said Luis Peña, President and Chief Executive Officer at Evommune. "With multiple programs now having positive Phase 2 data, we are poised to grow into a significant company in the immunology space," added Mr. Peña.

------

**Key data highlights include:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Primary Endpoint:** The trial met its primary endpoint; a Bayesian success criterion related to the difference between active and placebo in the percent improvement in baseline in the Eczema Area and Severity Index (EASI). While the success criterion required at least 75% of the posterior distribution to be an improvement of at least 8% over placebo, the results of the study demonstrated 99.8% of the posterior distribution met that threshold. Furthermore, when analyzed by the more commonly used frequentist method, statistical significance was achieved at weeks 4, 8 and 12 at p<0.01.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**% Reduction in EASI at weeks 4, 8 and 12:**

![img108483603_1.gif](img108483603_1.gif)

Additionally, 23% of patients treated with EVO301 (vs 0% placebo) achieved vIGA-AD 0/1 (percent of patients achieving a score of 0 or 1 on the validated Investigator's Global Assessment for Atopic Dermatitis with ≥ 2-point reduction from baseline) at week 12.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Pharmacokinetics ("PK"):** Consistent with the Phase 1 healthy volunteer trial; PK and target engagement data continue to support a Q4 week dosing regimen.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Safety Profile:** EVO301 was well tolerated, with no related serious or severe adverse events reported, no treatment related discontinuations due to adverse events and no meaningful differences in events between the active and placebo groups.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•**Biomarkers:** Robust reduction of both Th2 and non Th2 inflammatory biomarkers in AD including CCL-17 (TARC), CCL-22 and IL-22.

**Next Steps**

Full results from the Phase 2a trial will be presented at a future scientific conference. The Company continues to advance planning for a Phase 2b dose-ranging trial in patients with AD, using a subcutaneous formulation of EVO301. The Company is also evaluating potential additional indications for EVO301, including ulcerative colitis.

**Webcast Details**

Evommune will host a live conference call today at 8:30 a.m. ET. The live and archived webcast will be available on the News & Events page of the Company's website:

https://ir.evommune.com/news-events/ir-calendar. The webcast will be archived on the same page for 30 days following the event.

------

**About IL-18**

IL-18 is a known inflammatory pathway which plays a key role in various immune processes and acts as a key upstream therapeutic target for AD and other chronic inflammatory diseases. As an alarmin cytokine, IL-18 acts as a general amplifier of inflammation, capable of driving multiple inflammatory responses, including Th1, Th2, Th17/22 and innate pathways. This upstream position is crucial for treating conditions with heterogeneous inflammation, where targeting a single pathway may not be optimal. An upregulated IL-18 pathway cyclically activates inflammatory mediators in an aberrant manner, resulting in tissue damage and other inflammatory and sensory disease pathology. IL-18 directly disrupts essential barrier functions, positioning it as a pivotal pathogenic factor. Targeting IL-18 offers a novel broader therapeutic utility, simultaneously reducing inflammation and restoring tissue integrity for patients with complex inflammatory conditions.

**About EVO301**

EVO301 is a long-acting injectable SAFA-IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity. EVO301 facilitates more efficient tissue distribution and improved binding affinity and specificity relative to existing attempts to antagonize or inhibit the IL-18 pathway, including traditional mAbs. In addition, EVO301 incorporates several distinguishing design features, including selective and high binding affinity of native human IL-18BP and binding to serum albumin, smaller molecular weight, extended half-life for the neutralization of IL-18, and lower potential for immunogenicity. Evommune believes the distinct mechanism and modality of EVO301 complement those of EVO756, providing multiple, potentially synergistic avenues to bring innovative therapeutics to the large, underserved and rapidly expanding population of patients suffering from chronic inflammatory diseases.

**About Evommune, Inc.** 

Evommune, Inc., is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company's mission is to improve patients' daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn.

------

**Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company's product candidates, including the ongoing Phase 2 clinical trials for EVO756 and the planned Phase 2b trial for EVO301; the therapeutic potential of the Company's product candidates; the Company's ability to grow into a significant company in the immunology space; and the expected market opportunity for its lead programs. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company's limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company's ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company's ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q, filed with the SEC on December 11, 2025, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

**Disclosure:** Dr. Lebwohl serves as a compensated member of Evommune's Scientific Advisory Board.

------

**Contacts:**

**Media:** 

Paul Laland

<u>Paul.Laland@evommune.com</u>

**Investors:** 

Sarah McCabe

<u>investors@evommune.com</u>

------

## Exhibit 99.2

![Slide 1](evmn-ex99_2s1.jpg)

EVO301 Top-Line Results from Phase 2a Trial in Moderate-to-Severe Atopic Dermatitis February 10, 2026© Evommune, Inc.

------

![Slide 2](evmn-ex99_2s2.jpg)

Forward-Looking Statements© Evommune, Inc. Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements related to data supporting the Company's ongoing clinical trials, development of EVO301 in inflammatory diseases, EVO301 mechanism of action and EVO301 as a new treatment option for patients with moderate to severe atopic dermatitis; the potential safety and efficacy of the Company's product candidates; clinical strategy and the design of clinical trials, including the timeline for initiation, target or expected number of patients to be enrolled, dose levels, number of sites and other product development milestones; and the availability and timing of clinical and preclinical data announcements and clinical readouts, including data from the Phase 2a clinical trial for atopic dermatitis with EVO301. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and data from clinical trails not being predictive of future results; the Company's ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company's ability to raise additional capital. These and other risks are described more fully in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission (the "SEC") on December 11, 2025, as well as other documents that may be filed by the Company from time to time with the SEC. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. Such products are currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated. This presentation also contains estimates made by independent parties relating to industry market size and other data. These estimates involve a number of assumptions and limitations, and you are cautioned not to give undue weight on such estimates. We have not independently verified the accuracy or completeness of such information and we do not take any responsibility with the accuracy or completeness of such information. The trademarks included in this presentation are the property of the owners thereof and are used for reference purposes only.

------

![Slide 3](evmn-ex99_2s3.jpg)

Luis Peña Founder, President & CEO Mark Jackson, MD SVP, Clinical Development Agenda and Speakers Introduction Luis Peña Founder, President & CEO IL-18 Development Program Mark Jackson, MD SVP, Clinical Development EVO301 Phase 2a Data Mark Jackson, MD SVP, Clinical Development Closing Remarks Luis Peña Founder, President & CEO 3© Evommune, Inc.

------

![Slide 4](evmn-ex99_2s4.jpg)

5v Our Mission-Driven Approach to Treating Immune-Mediated Diseases© Evommune, Inc. Two Phase 2 Programs with Diverse Approaches Targeting Heterogeneous Diseases EVO756: Oral Therapy Targeting Mast Cells and Sensory Neurons EVO301: IL-18 Blockade for Multi-Pathway Immunomodulation Address critical gaps in care… Expansive Portfolio of Preclinical Programs Sensory Neuron Mast Cell MRGPRX2 Nerves Mast Cells Novel Biologic Using the Fully Human IL-18 Binding Protein Adaptive (Th2) Inflammation Innate Inflammation …Strategically select mechanisms with strong probability of success… … Steady cadence of new programs entering the clinic

------

![Slide 5](evmn-ex99_2s5.jpg)

Our Inflammation Portfolio and the Role of EVO301© Evommune, Inc. Program / Target Indication Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone EVO756 MRGPRX2 Chronic Spontaneous Urticaria Phase 2b Data (H1 2026) Atopic Dermatitis Phase 2b Data (H2 2026) Other Indications Phase 2 Trial Initiation (2026) EVO301 IL-18 Atopic Dermatitis Positive Phase 2a POC: Full Data to be presented at an upcoming medical meeting Phase 2b Trial planning underway Ulcerative Colitis Phase 2 Trial planning underway Advancing Multiple Preclinical Programs Toward Clinical Proof-of-Concept

------

![Slide 6](evmn-ex99_2s6.jpg)

IL-18 Drives Various Innate and Adaptive Immune Processes Related to Infection, Inflammation and Autoimmunity© Evommune, Inc. PAMPs: Pathogen-associated molecular patterns; DAMPs: Damage-associated molecular patterns Chronic Inflammation Tissue Pathophysiology Clinical Manifestations Inflammatory Infiltrates Inflammatory Cytokines Autoimmunity Angiogenesis Th1, 2, 17 Differentiation Barrier Dysfunction Infection Tissue Damage Pathogen Clearance IL-18BP Therapeutic Approach Involved in Innate and Adaptive Immune Processes IL-18 producing cells IL-18 responding cells Stromal/mesenchymal IL-18 Epithelial Endothelial CD4 T NK CD8 T Macrophage Dendritic cell Dendritic cell Macrophage Dysbiosis Tissue Injury Infection DAMPs\* PAMPs\* IL-18R1 IL-18RAP No Response Activation IL-18 IL-18BP Epithelial Barrier

------

![Slide 7](evmn-ex99_2s7.jpg)

EVO301: Long-Acting IL-18 Neutralizer Designed for Tissue TargetingSAFA\* and IL-18BP fused via peptide linker for extended neutralization of IL-18 activity© Evommune, Inc. SAFA - Anti-Serum Albumin Fab-Associated. HAS – Human Serum Albumin SAFABODY™ is a trademark of AprilBio Co., Ltd. SAFAbody™ Platform Technology T½ extension: FcRn-mediated recycling of HSA Efficient tissue distribution: Smaller size and HSA binding IL-18 Binding Protein (IL-18BP) High binding affinity and specificity Functional activity comparable to IL-18 Mab Native fully human sequence MW ~65 kD

------

![Slide 8](evmn-ex99_2s8.jpg)

Biologic Pathway Adaptive Inflammation Innate Inflammation Skin Barrier (IL-22) TH2 TH1 TH17 IL-18 IL-4 / -13 IL-18 Impacts Multiple Inflammatory Pathways that Drive Atopic Dermatitis© Evommune, Inc. Green = impacts biological pathway; Red = negative effect. IL-18 modulation of broader immunological cascades beyond Th2 is a key differentiator in AD

------

![Slide 9](evmn-ex99_2s9.jpg)

EVO301 Achieved the Primary EndpointPhase 2a Proof-of-Concept Trial in Moderate-to-Severe Atopic Dermatitis Highly statistically significant EASI reductions at weeks 4, 8, and 12 versus placebo 34% and 33% placebo adjusted improvement in EASI at week 8 and 12, respectively 23% of patients achieved IGA 0/1 at week 12 versus 0% placebo Well-tolerated, with no treatment related serious or severe adverse events reported Corresponding reductions in secondary endpoints, as well as key Th2 and non Th2 cytokines Pharmacokinetics (PK) continues to support a Q4 week dosing regimen© Evommune, Inc. Clinical Data Supports Continued Development, with Phase 2b Planning Underway

------

![Slide 10](evmn-ex99_2s10.jpg)

EVO301 Phase 2a Proof of Concept Trial Design© Evommune, Inc. EASI = Eczema Area and Severity Index; vIGA = Validated Investigator Global Assessment; BSA = Body Surface Area; BL = Baseline; PBO = Placebo Screening Randomization 2 Active : 1 PBO End of Trial BL W12 W4 Adults with Moderate-to-Severe Atopic Dermatitis (N = 70) Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial AD Population EASI ≥16 vIGA ≥3 BSA ≥10% Primary Endpoint Percent change from EASI at Week 12 (Bayesian) Pharmacokinetics Target Engagement W8 EVO301: 5 mg/kg IV Placebo Dosing day Dosing day W2

------

![Slide 11](evmn-ex99_2s11.jpg)

Disposition, Baseline Demographics and Disease Characteristics© Evommune, Inc. Note: Numbers in parentheses are standard deviations. BMI: body mass index, EASI: Eczema Area and Severity Index, IGA: Investigator's global assessment, NRS: numeric rating score, BSA: body surface area, SD: standard deviation. Subjects who were early terminations were 1. Lost to follow-up. 2. Lost to follow-up and subject withdrawal Trial well-balanced across cohorts EVO301 Placebo N (treated) 48 22 N (completed) 451 202 Age 30.5 (11.1) 33.1 (11.8) Gender (female, %) 29 (60.4%) 13 (59.1%) Weight (kg) 78.5 (18.7) 76.4 (17.5) BMI (kg/m2) 27.4 (6.0) 28.1 (6.3) EASI 30.0 (11.8) 29.8 (10.5) IGA 3.3 (0.5) 3.5 (0.5) Pruritus-NRS 6.3 (1.5) 6.7 (2.1) % BSA 47.1 (21.2) 49.3 (16.1)

------

![Slide 12](evmn-ex99_2s12.jpg)

Phase 2a Trial in AD Met Primary Outcome Measure (Bayesian) EASI: Eczema Area and Severity Index, SD: standard deviation, HPD: high posterior density % Change in EASI at Week 12: Protocol Success Criterion Met Statistic EVO301 versus Placebo Success Criterion: Posterior Probability of Difference < -8% 75% Trial Results: Posterior Probability of Difference < -8% 99.76% Posterior Mean Difference -28 95% HPD Interval for Difference in Mean -43, -14© Evommune, Inc.

------

![Slide 13](evmn-ex99_2s13.jpg)

Phase 2a Trial in AD Demonstrated Statistically Significant Efficacy Across Time Points EASI: Eczema Area and Severity Index, LS mean: least squares mean, SE: standard error, CI: confidence interval % Change in EASI by Study Visit Visit EVO301 Placebo Placebo-adjusted Change p-value Week 4 -41 -18 -23 <0.01 Week 8 -50 -16 -34 <0.01 Week 12 -55 -22 -33 <0.01© Evommune, Inc.

------

![Slide 14](evmn-ex99_2s14.jpg)

Week 2 Phase 2a Trial in AD Demonstrated Statistically Significant Efficacy Across Time Points© Evommune, Inc. Week 0 Week 4 Week 8 Week 12 % Average Change in EASI ↓ Dosed at Weeks 0 and 4 Placebo EVO301 \* \* % Change in EASI by Study Visit \*p<0.01 ↓ % Average change in EASI is LS Mean -22 -18 -16 -22 -30 -41 -50 -55 ↓ \*

------

![Slide 15](evmn-ex99_2s15.jpg)

IL-18 IL-31 IL-13 IL-4 / IL-13 Two Doses of EVO301 Demonstrated Comparable Activity at 12 Weeks to Dose-Optimized Marketed Biologics at 16 Weeks© Evommune, Inc. For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and study characteristics, and caution should be exercised when comparing across trials. Sources: Silverberg et al. (2016), Silverberg et al. (2023), Wollenberg et al. (2020), Ruzicka et al. (2017). Placebo-Adjusted % Improvement from Baseline in EASI Dose-Optimized Products # Doses: 2 8 8 8 8 8 8 3 EVO301 EVO301-AD001 Phase 2a 12 week N = 70 5 mg/kg IV Dupixent® SOLO 1 Phase 3 16 week N=671 600 mg W0 300 mg Q2W Dupixent® SOLO 2 Phase 3 16 week N=708 600 mg W0 300 mg Q2W Ebglyss™ ADVOCATE 1 Phase 3 16 week N=424 500 mg W0, W2 250 mg Q2W Ebglyss™ ADVOCATE 2 Phase 3 16 week N=427 500 mg W0, W2 250 mg Q2W Adbry® ECZTRA 1 Phase 3 16 week N=802 300 mg Q2W Adbry® ECZTRA 2 Phase 3 16 week N=794 300 mg Q2W Nemluvio® Phase 2a 12 week N=264 2 mg/kg QW4

------

![Slide 16](evmn-ex99_2s16.jpg)

↑ Week 0 ↑ Week 4 Week 8 Week 12 vIGA Response Phase 2a Trial in AD: Early Clinical Signal in vIGA 0/1 Response© Evommune, Inc. vIGA: Validated Investigator's Global Assessment Visit EVO301 Placebo Week 4 4.2% 0% Week 8 12.5% 0% Week 12 22.9% 0% vIGA Response (≥2-pt improvement and a score of 0 or 1) ↑ Dosed at Weeks 0 and 4 Placebo EVO301

------

![Slide 17](evmn-ex99_2s17.jpg)

Additional Endpoints and Target Engagement© Evommune, Inc. Full Detailed Results Will Be Presented at a Future Scientific Conference PK and target engagement data continue to support a Q4 week dosing regimen Corresponding reductions in secondary endpoints Corresponding reduction of key Th2 associated biomarkers (CCL-17 (TARC), CCL-22) and non-Th2 associated biomarkers (IL-22)

------

![Slide 18](evmn-ex99_2s18.jpg)

Safety Summary Over 12 Week Trial PeriodEVO301 Was Well Tolerated© Evommune, Inc. No Clinically Significant Lab Abnormalities. No Conjunctivitis Reported (as is Common with Other Biologics in AD) EVO301 Placebo Total N=48 N=22 N=70 Patients with ≥1 Adverse Event (AE) 30 (62.5%) 16 (72.7%) 46 (65.7%) Patients with ≥1 Treatment Related AE 5 (10.4%) 3 (13.6%) 8 (11.4%) Patients with a Related Serious or Severe AE 0 0 0 AEs Leading to Study Discontinuation 0 0 0 AEs > 5% in Either Arm EVO301 Placebo Total Upper respiratory tract infection 10 (20.8%) 4 (18.2%) 14 (20.0%) Atopic dermatitis 10 (20.8%) 9 (40.9%) 19 (27.1%) Headache 8 (16.7%) 3 (13.6%) 11 (15.7%) Nasopharyngitis 4 (8.3%) 0 4 (5.7%) Viral upper respiratory tract infection 3 (6.3%) 2 (9.1%) 5 (7.1%) Dizziness 3 (6.3%) 1 (4.5%) 4 (5.7%) Fatigue 3 (6.3%) 0 3 (4.3%)

------

![Slide 19](evmn-ex99_2s19.jpg)

Atopic Dermatitis: Large and Growing MarketExpansion of AD Market Outpacing That of Psoriasis© Evommune, Inc. Per Evaluate Pharma (May represent projections and not actual sales); "Year 1" for AD represents 2017 (year of Dupixent launch); "Year 1" for psoriasis represents 2004 (year of Enbrel launch in plaque psoriasis); 1. Total estimated prevalence in adult and pediatric populations; Estimated per Allergy & Asthma Network, Hanafin & Reed (2007), AAFA, Fuxench et al, (2019); 2. Total estimated prevalence in adult and pediatric populations; Estimated per psoriasis.org, datacenter.aecf.org, Armstrong et al. (2021), Paller et al. (2018), Tannenbaum et al. (2022), Helmick et al. (2014), Rosario-Jansen et al. (2025). Note that slide contains registered trademarks not owned by Evommune 0 5 10 15 20 25 0 5 10 15 20 25 Year After Market Entry of First Advanced Therapy US Sales ($B) Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10 Y11 Y12 Y13 Y14 Y15 Y16 Y17 Y18 Y19 Y20 Y21 Dupixent (IL-4 / IL-13) Adbry (IL-13) Rinvoq (JAK1) Ebglyss (IL-13) Other Skyrizi (IL-23) Tremfya (IL-23) Stelara (IL-12/IL-23) Cosentyx (IL-17A) Taltz (IL-17A) Bimzelx (IL-17A/IL-17F) Humira (TNFα) Enbrel (TNFα) Remicade (TNFα) Otezla (PDE4) Other Atopic Dermatitis Mod-to-Sev Patients ≈ 13M 1 Where We are Today in the AD Market Psoriasis Growth Driven by Nine Blockbusters Spanning Six MOAs. AD Remains a Concentrated Market with Clear Opportunity for Additional Advanced Therapies. Stelara (IL-12 / IL-23) Bimzelx (IL-17A / IL-17F) Psoriasis Mod-to-Sev Patients ≈ 1.4M 2

------

![Slide 20](evmn-ex99_2s20.jpg)

Summary and Path Forward to Phase 2b and Beyond© Evommune, Inc. IL-18 modulation of broader immunological cascades beyond Th2 is a key differentiator in AD EVO301 provides unique approach to IL-18 targeting, as a long-acting fusion protein consisting of a binding protein and an anti-serum albumin Fab EVO301 achieved the primary endpoint in the Ph2a POC trial Highly statistically significant efficacy at weeks 4, 8 and 12, after just two doses of EVO301 23% of EVO301 patients achieved IGA 0/1 at week 12 Full results from Phase 2a trial will be presented at a future scientific conference Clinical data clearly support continued development IL-18 biology extends far beyond AD, with IL-18 upregulated across a number of inflammatory diseases Phase 2b planning underway for AD with SubQ formulation, with POC planning underway for Ulcerative Colitis Multiple Drivers of Value Differentiated Mechanism with Broad Potential Clear Efficacy in AD

------

![Slide 21](evmn-ex99_2s21.jpg)

With Two Clinically Validated Programs, Evommune Continues to Deliver on our Strategy© Evommune, Inc. Program / Target Indication Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone EVO756 MRGPRX2 Chronic Spontaneous Urticaria Phase 2b Data (H1 2026) Atopic Dermatitis Phase 2b Data (H2 2026) Other Indications Phase 2 Trial Initiation (2026) EVO301 IL-18 Atopic Dermatitis Positive Phase 2a POC: Full Data to be presented at an upcoming medical meeting Phase 2b Trial planning underway Ulcerative Colitis Phase 2 Trial planning underway

------

![Slide 22](evmn-ex99_2s22.jpg)

Q&A© Evommune, Inc.

------

![Slide 23](evmn-ex99_2s23.jpg)

Appendix© Evommune, Inc.

------

![Slide 24](evmn-ex99_2s24.jpg)

Moderate-to-Severe Atopic Dermatitis: Heterogenous Disease that is Prevalent, Impactful, and Underserved© Evommune, Inc. Source: Habif's Clinical Dermatology: A Color Guide to Diagnosis and Therapy. National Eczema Association (accessed 2026), Luckhaupt, et al. (2013). Dupixent Prescribing Information. Rinvoq Prescribing Information. Substantial Need for Broad, Safe Treatments ~13M Americans live with moderate-to-severe atopic dermatitis Chronic, relapsing disease characterized by relentless itch and visible inflammation Significant quality-of-life impact ~40% of patients inadequately controlled with current therapies

------

![Slide 25](evmn-ex99_2s25.jpg)

IL-18 Shows Similar Efficacy to IL-4 targeting Agents in vivo Study design: SK-1 hairless mice were sensitized with 100 ul of 3% oxazolone on Day 0. On Day 7, mice were challenged with 100ul of 0.3% oxazolone on the back, three times a week. Cumulative score = sum of score (0-4) for erythema, scaling, and thickness. A B C D E F G \*\*\* \*\*\* \*\*\* \*\*\* \*\*\* \* \*\*\* Normal Vehicle Anti-IL4Ra Ab 3 mg/kg Anti-IL18 Ab 10 mg/kg EVO301 1 mg/kg EVO301 3 mg/kg EVO301 10 mg/kg in vivo: Suppression of Oxazolone-Induced Atopic Dermatitis© Evommune, Inc.

------

![Slide 26](evmn-ex99_2s26.jpg)

Phase 2a Trial in AD: Primary Outcome Measure (Bayesian)Posterior Distribution Curves© Evommune, Inc. % Change in EASI by Study Visit (Placebo Adjusted) EASI: Eczema Area and Severity Index -8 Week 12 Week 2 Week 4 Week 8 -32.5 -28.2 -21.5 -7.1 % Change in EASI 0 -20 -40 Density 0.06 – 0.04 – 0.02 – 0.00 –

------

![Slide 27](evmn-ex99_2s27.jpg)

IL-18 Biology Extends Beyond Atopic Dermatitis, Supporting Multi-Indication Value Creation for EVO301© Evommune, Inc. Neurologic Multiple Sclerosis • Myasthenia Gravis • Multi-Organ • Systemic Lupus Erythematosus • Dermatomyositis & Polymyositis Other • Adult Onset Still Disease • Rheumatoid Arthritis • Psoriatic Arthritis • Fibrotic Diseases (NASH, PBC) • Type 1 Diabetes Respiratory • Pulmonary Sarcoidosis Cutaneous Atopic Dermatitis • Psoriasis • Digestive Ulcerative Colitis • Crohn's Disease •